Main Menu

ANDA Litigation Book Reviewed by DrugPatentWatch

News & Media Mentions

Kenneth L. Dorsney, Editor-in-Chief

March 22, 2019

Ken Dorsney The second edition of ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators was reviewed favorably by DrugPatentWatch, a business who serves leading companies ranging from biopharmaceutical R&D to healthcare delivery by providing actionable business intelligence on small-molecule drugs. 

Morris James partner Ken Dorsney is the Editor-in-Chief and Co-Author of the ABA's ANDA Litigation: Strategies and Tactic for Pharmaceutical Patent Litigators, first and second editions, AIPLA and Bloomberg Law's Evidence in Patent Cases, and the ABA's Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, first and second editions.

According to DrugPatentWatch, ANDA Litigation is a vital resource for parties involved in protecting branded drugs or in generic drug launch. The price, which is relatively low for a book of this size and scope, should be recouped quickly by avoiding costly strategic and tactical missteps, and in savings on legal expenses.

View the full book review here.



Practice Areas

Back to Page